<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887029</url>
  </required_header>
  <id_info>
    <org_study_id>OCC1023</org_study_id>
    <nct_id>NCT00887029</nct_id>
  </id_info>
  <brief_title>A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma</brief_title>
  <acronym>DVX</acronym>
  <official_title>A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmic Consultants Centres, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ophthalmic Consultants Centres, Canada</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

        -  H1: Efficacy of Duotrav will be superior to Xalacom at 24 hours post dosing when both
           medications are given in the morning

        -  H2: A significant proportion of patients will prefer dosing of once daily topical fixed
           combination therapy in the morning compared to evening dosing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Primary objective: Compare IOP-lowering efficacy of morning dosing of Duotrav to
           Xalacom.

        -  Secondary objective: Compare patient dosing preferences for topical prostaglandin
           therapy in terms of convenience and perceived compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP lowering efficacy of DuoTrav and Xalacom</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare patient dosing preferences in terms of convenience and perceived compliance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>DuoTrav</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalacom</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DuoTrav (travoprost-timolol ophthalmic drops)</intervention_name>
    <description>topical ophthalmic drops instilled 1 drop daily</description>
    <arm_group_label>DuoTrav</arm_group_label>
    <other_name>DuoTrav</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalacom (latanoprost-timolol ophthalmic drops)</intervention_name>
    <description>topical ophthalmic drops instilled 1 drop daily</description>
    <arm_group_label>Xalacom</arm_group_label>
    <other_name>Xalacom</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years old, diagnosed with primary open angle glaucoma or ocular
             hypertension

          -  IOP currently uncontrolled on beta blocker monotherapy, as judged by the investigator

          -  Response to Timolol 0.5% was a ≥10% reduction in IOP

          -  IOP at 9:00 of ≥ 20 mmHg while still on beta blocker

          -  Non-prescription and prescription topical ophthalmic products and systemic medications
             other than those mentioned in the exclusion criteria will be allowed during the study.

          -  Patients wearing contact lenses will be permitted to participate in the study provided
             that the contact lenses are removed during instillation of study medication and that
             the patient waits fifteen (15) minutes following drug instillation to re-insert the
             lenses. Contact lenses cannot be worn on study days.

        Exclusion Criteria:

          -  Best corrected visual acuity worse than 0.6 logMAR or 20/80 Snellen in either eye.

          -  Patients in whom the mean IOP in either eye at the screening exam visit is greater
             than 36 mmHg

          -  History of ocular trauma within the past six (6) months.

          -  History of ocular infection or ocular inflammation within the past three (3) months.

          -  History of chronic or recurrent severe inflammatory eye disease (i.e., scleritis,
             uveitis)

          -  History of severe or serious hypersensitivity to any components of the study
             medications.

          -  Any abnormality preventing reliable applanation tonometry of either eye.

          -  Intraocular surgery within the past six (6) months as determined by patient history
             and/or examination.

          -  Patients with cup/disc ratio greater than 0.80 in either eye.

          -  Patients with severe central visual field loss in either eye defined as a sensitivity
             10 dB in at least two (2) of the four (4) visual field test points closest to the
             point of fixation.

          -  History of severe retinal disease such as retinal degeneration, diabetic retinopathy
             or retinal detachment.

          -  Current use of ANY glucocorticoid administered by any route. Patient must have washed
             out of the glucocorticoid for at least 4 weeks prior to study entry.

          -  Use of any systemic prostaglandin or prostaglandin analogue (e.g., CYTOTEC) within the
             last three months.

          -  Current use of topical non-steroidal anti inflammatory agents which inhibit
             cyclo-oxygenase and prostaglandin analogue synthesis.

          -  Any form of glaucoma other than open-angle glaucoma (with or without a pigment
             dispersion or pseudoexfoliation component).

          -  Current use of topical non-steroidal anti inflammatory agents which inhibit
             cyclo-oxygenase and prostaglandin analogue synthesis

          -  Angle grade less than 2 (extreme narrow angle with complete or partial closure) as
             measured by gonioscopy.

          -  Therapy with another investigational agent within the past 30 days

          -  Patients who would be at risk from treatment with a topical prostaglandin or
             prostaglandin analogue, are contraindicated for use of beta-blockers or any other
             medication used in this study, or who would be at risk from participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultant Centres</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Navroop Gill, OD</last_name>
    <role>Study Chair</role>
    <affiliation>Ophthalmic Consultant Centres</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Consultant Centres</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr David B. Yan, M.D., F.R.C.S.C.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R2M8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001 Oct;132(4):472-84.</citation>
    <PMID>11589866</PMID>
  </results_reference>
  <results_reference>
    <citation>Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004 Jan;26(1):84-91.</citation>
    <PMID>14996520</PMID>
  </results_reference>
  <results_reference>
    <citation>Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007 Mar-Apr;17(2):183-90.</citation>
    <PMID>17415690</PMID>
  </results_reference>
  <results_reference>
    <citation>Diestelhorst M, Larsson LI; European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004 Feb;88(2):199-203.</citation>
    <PMID>14736774</PMID>
  </results_reference>
  <results_reference>
    <citation>Yan DB, Battista RA, Haidich AB, Konstas AG. Comparison of morning versus evening dosing and 24-h post-dose efficacy of travoprost compared with latanoprost in patients with open-angle glaucoma . Curr Med Res Opin. 2008 Nov;24(11):3023-7. doi: 10.1185/03007990802426813 . Epub 2008 Oct 14.</citation>
    <PMID>18826749</PMID>
  </results_reference>
  <results_reference>
    <citation>Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743-52.</citation>
    <PMID>9098273</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical prostaglandin analogue</keyword>
  <keyword>glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>OHT</keyword>
  <keyword>OAG</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>fixed combination protaglandin analogue therapy</keyword>
  <keyword>DuoTrav</keyword>
  <keyword>timolol</keyword>
  <keyword>travoprost</keyword>
  <keyword>24 hour post dose</keyword>
  <keyword>IOP</keyword>
  <keyword>dosing preference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

